BMS-backed liquid biopsy biotech Precede Biosciences debuts to enhance precision medicine approaches
Precede Biosciences has emerged with a liquid biopsy platform that can illuminate a patient’s biological state and would serve as the foundation for blood tests to help drugmakers build a picture of patients likely to respond to treatments.
Many precision medicine efforts have focused on gene mutations, but the Boston, MA-based company has a broader approach. “There are so many other contexts that are non-mutationally driven. Where there’s a [non-mutational] molecular mechanism underlying the disease… we’re focused on addressing those,” CEO Rehan Verjee told Endpoints News in an interview.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.